Caprock Group LLC Reduces Position in HCA Healthcare, Inc. (NYSE:HCA)

Caprock Group LLC decreased its position in HCA Healthcare, Inc. (NYSE:HCA) by 13.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,166 shares of the company’s stock after selling 1,425 shares during the quarter. Caprock Group LLC’s holdings in HCA Healthcare were worth $2,751,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of HCA. Legacy Investment Solutions LLC acquired a new position in HCA Healthcare in the 3rd quarter valued at $39,000. Canoe Financial LP acquired a new position in HCA Healthcare in the third quarter valued at $41,000. Capital Performance Advisors LLP purchased a new stake in HCA Healthcare in the 3rd quarter valued at about $41,000. Northwest Investment Counselors LLC acquired a new stake in shares of HCA Healthcare in the third quarter worth approximately $44,000. Finally, Pinnacle Bancorp Inc. increased its position in HCA Healthcare by 50.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 150 shares of the company’s stock worth $45,000 after purchasing an additional 50 shares during the last quarter. 62.73% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at HCA Healthcare

In related news, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the transaction, the senior vice president now directly owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the transaction, the insider now owns 6,843 shares in the company, valued at approximately $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

HCA Healthcare Stock Performance

HCA opened at $330.24 on Friday. HCA Healthcare, Inc. has a 1-year low of $289.98 and a 1-year high of $417.14. The company has a market capitalization of $83.65 billion, a price-to-earnings ratio of 15.03, a price-to-earnings-growth ratio of 1.12 and a beta of 1.64. The business has a 50 day moving average price of $313.33 and a two-hundred day moving average price of $353.05. The company has a debt-to-equity ratio of 69.07, a current ratio of 1.08 and a quick ratio of 0.97.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same quarter last year, the business posted $5.90 earnings per share. Research analysts predict that HCA Healthcare, Inc. will post 24.91 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be paid a dividend of $0.72 per share. The ex-dividend date is Monday, March 17th. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.66. This represents a $2.88 dividend on an annualized basis and a yield of 0.87%. HCA Healthcare’s dividend payout ratio is currently 12.02%.

Wall Street Analysts Forecast Growth

HCA has been the subject of a number of research analyst reports. Morgan Stanley dropped their price objective on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Truist Financial reduced their price objective on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. KeyCorp reduced their price target on shares of HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Barclays cut their target price on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Finally, Wells Fargo & Company lowered HCA Healthcare from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $400.00 to $320.00 in a research report on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $385.67.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.